Human serum albumin (HSA) participates in heme scavenging; in turn, heme endows HSA with myoglobin-like reactivity and spectroscopic properties. Here, the allosteric effect of ibuprofen on peroxynitrite isomerization to NO 3 ؊ catalyzed by ferric human Human serum albumin (HSA), 3 the most abundant protein in plasma (reaching a blood concentration of about 7.0 ϫ 10 Ϫ4 M), is characterized by an extraordinary ligand binding capacity, providing a depot and carrier for many compounds. HSA affects the pharmacokinetics of many drugs; holds some ligands in a strained orientation, providing their metabolic modification; renders potential toxins harmless, transporting them to disposal sites; accounts for most of the antioxidant capacity of human serum; and displays (pseudo)enzymatic properties (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) .
HSA is a single non-glycosylated all-␣-chain protein constituted by 585 amino acids, containing three homologous domains (labeled I, II, and III). Each domain is made up by two separate helical subdomains (named A and B), connected by random coils. Terminal regions of sequential domains contribute to the formation of interdomain helices linking domain IB to IIA and domain IIB to IIIA, respectively ( Fig. 1) (2, 3, 5, 7, 11, (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) .
The structural organization of HSA provides a variety of ligand binding sites (Fig. 1) . According to Sudlow's nomenclature, bulky heterocyclic anions bind preferentially to Sudlow's site I (located in subdomain IIA), whereas Sudlow's site II (located in subdomain IIIA) is preferred by aromatic carboxylates with an extended conformation (Fig. 1 ). Warfarin and ibuprofen are considered as stereotype ligands for Sudlow's site I and II, respectively (1-3, 5, 12, 14, 16, 20, 26 -30) .
HSA is able to bind seven equivalents of long-chain fatty acids (FAs) at multiple binding sites (labeled FA1-FA7 in Fig. 1 ) with different affinity (24, 31) . In particular, FA1 is located within the IB subdomain, contacting the IB-IIA polypeptide linker and the long IB-IIA transdomain helix; FA2 is located at the interface between subdomains IA, IB, and IIA; FA3 and FA4 together contribute to Sudlow's site II (i.e. the ibuprofen site in subdomain IIIA); FA5 is located within subdomain IIIB with the ligand polar head oriented toward subdomain IIIA; FA6 is at the interface between subdomains IIA and IIB; FA7 corresponds to Sudlow's site I (i.e. the warfarin binding site in subdomain IIA). FA2 and FA6 clefts appear to be the secondary binding sites of ibuprofen (1, 3, 12, 14, 16, 18 -20, 32-35) .
The FA1 binding site has been shown to be the primary binding site for heme, bilirubin, and fusidic acid, an antibiotic that competitively displaces bilirubin from HSA (14, 21, 23) . There is increasing evidence that FA1 has evolved to selectively bind heme-Fe(III) with high affinity (K d ϭ 1.0 ϫ 10 Ϫ8 M) (21, 23-25, 36, 37) . The tetrapyrrole ring is arranged in a D-shaped cavity limited by Tyr 138 and Tyr 161 residues that provide -stacking interactions with the porphyrin and supply a donor oxygen (from Tyr 161 ) for the heme-Fe(III) atom. HemeFe(III) is secured to HSA by the long IA-IB connecting loop (21, 23-25, 36 -38) . In turn, heme endows HSA with myoglobin (Mb)-like reactivity and spectroscopic properties (11, 21, 23, 28, 30, 36 -55) .
Both heme-Fe(III) binding to HSA and HSA-heme-Fe(II) reactivity are modulated allosterically, such that HSA-heme could be considered as a prototype monomeric allosteric macromolecule (21, 23-25, 30, 36 -38, 45, 48, 52, 56) . Indeed, the affinity of the heme-Fe(III) for HSA decreases by about 1 order of magnitude upon drug (e.g. warfarin) binding; on the other hand, heme-Fe(III) binding to HSA decreases the drug affinity by the same extent (57) . Further, heme-Fe(III) inhibits ligand binding to Sudlow's site I by stabilizing the basic state of HSA, whereas ligand association to Sudlow's site I impairs HSA-heme-Fe(III) formation by stabilizing the neutral state of HSA (21, 23-25, 30, 36, 52, 56) . Moreover, heme-Fe(III) modulates competitively and allosterically FA binding to HSA, since myristate binding to all FA sites competes with heme-Fe(III) binding to FA1 and at the same time induces the neutral to basic transition, facilitating heme-Fe(III) binding (5, 13, 23, 25, 37) . In addition, abacavir and warfarin have been reported to modulate allosterically peroxynitrite-mediated oxidation of ferrous nitrosylated HSA (HSA-heme-Fe(II)-NO) (50) and NO dissociation from HSA-heme-Fe(II)-NO (51).
Here, ibuprofen, the prototype ligand of Sudlow's site II (1, 3, 26, 58) , is reported to impair peroxynitrite 4 isomerization to NO 3 Ϫ by HSA-heme-Fe(III), in the absence and presence of CO 2 . In the absence of ibuprofen, the pentacoordinated HSAheme-Fe(III) form catalyzes peroxynitrite isomerization to NO 3 Ϫ , preventing the nitration of free added L-tyrosine. In contrast, ibuprofen induces hexacoordination of the heme-Fe(III) atom of HSA-heme-Fe(III), impairing allosterically peroxynitrite isomerization by HSA-heme-Fe(III) and allowing the nitration of free added L-tyrosine. These results represent the first evidence for a drug-dependent peroxynitrite scavenging by HSA-heme-Fe(III), a condition possibly occurring in patients with various hemolytic diseases (59) .
EXPERIMENTAL PROCEDURES

Materials
Hemin (Fe(III)-protoporphyrin IX) chloride was purchased from Sigma. The heme stock solution (5.0 ϫ 10 Ϫ3 M) was prepared by dissolving heme-Fe(III) in 1.0 ϫ 10 Ϫ2 M NaOH (60). The heme-Fe(III) concentration was determined spectrophotometrically at 535 nm, after converting heme-Fe(III) to the heme-Fe(III)-bisimidazolate derivative by adding 1.0 M imidazole, in SDS micelles (⑀ 535 nm ϭ 14.5 ϫ 10 3 M Ϫ1 cm Ϫ1 ) (61) . HSA (Ն96%, essentially fatty acid-free) was obtained from Sigma. To remove hydrophobic ligands, HSA was dissolved in water, acidified to pH 3.5 with acetic acid, and treated for 2 h with activated charcoal at room temperature. After charcoal removal by centrifugation, the pH was brought to 7.0 with aqueous ammonia (62) . The HSA concentration was determined spectrophotometrically at 280 nm (⑀ 280 nm ϭ 38.2 ϫ 10 3 M Ϫ1 cm
Ϫ1
) (60) . The HSA stock solution (2.0 ϫ 10 Ϫ4 M) was prepared by diluting the hydrophobic ligand-free HSA solution with the 2.0 ϫ 10 Ϫ2 M sodium phosphate buffer, at pH 7.2. The HSA-heme-Fe(III) stock solution (2.0 ϫ 10 Ϫ4 M) was prepared by adding a 0.9-fold molar defect of the heme-Fe(III) stock solution to the HSA solution (2.0 ϫ 10 Ϫ2 M sodium phosphate buffer, pH 7.2) (30, 37, 42, 44, 50, 54, 55, 60, 63) . The HSA and HSA-heme(III) stock solutions were diluted in the 2.0 ϫ 10 Ϫ1 M sodium phosphate buffer at the desired pH value (ranging between 6.2 and 8.1) and concentration (ranging between 1.0 ϫ 10 Ϫ5 and 1.0 ϫ 10
Peroxynitrite was synthesized from KO 2 and ⅐ NO and from HNO 2 and H 2 O 2 and stored in small aliquots at Ϫ80.0°C (64, 65) . The peroxynitrite stock solution (2.0 ϫ 10 Ϫ3 M) was diluted immediately before use with degassed 5.0 ϫ 10 Ϫ2 M NaOH to reach the desired concentration (50, 66 -69) . Nitrate and nitrite contaminations were in the range of 0 -7% and 8 -19% of the peroxynitrite concentration, respectively (see "Methods"). The concentration of peroxynitrite was determined spectrophotometrically prior to each experiment by measuring the absorbance at 302 nm (⑀ 302 nm ϭ 1.705 ϫ 10 3 M Ϫ1 cm Ϫ1 ) (64, 65 of bicarbonate, the protein solutions were allowed to equilibrate for at least 5 min. For the experiments carried out in the absence of CO 2 , all solutions were thoroughly degassed and kept under nitrogen or helium (50, 66 -69) . Experiments in the presence of cyanide at pH 7.2 were carried out by adding 2.0 ϫ 10 Ϫ1 M cyanide to the HSA-heme(III) and peroxynitrite/ibuprofen/L-tyrosine solutions, in the absence and presence of CO 2 . This cyanide concentration allowed to obtain more than 90% of HSA-heme-Fe(III)-cyanide complex (HSA-heme-Fe(III)-CN) (43, 52) .
Ibuprofen was obtained from Sigma. The ibuprofen stock solution (1.0 ϫ 10 Ϫ2 M) was prepared by dissolving the drug in 2.0 ϫ 10 Ϫ2 M phosphate buffer at pH 7.2 (30) . The final ibuprofen concentration ranged between 5.0 ϫ 10 Ϫ5 and 1.0 ϫ 10
L-Tyrosine and nitro-L-tyrosine were obtained from Sigma. L-Tyrosine and nitro-L-tyrosine were dissolved in 1.0 ϫ 10 Ϫ1 M phosphate buffer, at pH 7.2; the final L-tyrosine concentration was 1.0 ϫ 10 Ϫ4 M (67, 70) . All of the other chemicals were obtained from Sigma and Merck. All products were of analytical or reagent grade and were used without further purification.
Methods
The kinetics of peroxynitrite isomerization in the absence and presence of HSA-heme-Fe(III), HSA-heme-Fe(III)-CN, HSA, CO 2 , ibuprofen, and L-tyrosine was recorded with the SMF-20 and SMF-400 rapid mixing stopped-flow apparatus (Bio-Logic SAS, Claix, France). The light path of the observation cuvette was 10 mm, and the dead time was 1.4 ms. The kinetics was monitored at 302 nm, the characteristic absorbance maximum of peroxynitrite (64, 65) . Kinetic data were obtained in the absence and presence of CO 2 The kinetics of peroxynitrite isomerization in the absence and presence of HSA-heme-Fe(III) was analyzed in the framework of the minimum reaction Schemes 1 and 2, respectively (67, 70) ,
Values of the first-order rate constant for peroxynitrite isomerization in the presence of HSA-heme-Fe(III)-CN, HSA, and 
The pH dependence of k 0 and k on for peroxynitrite isomerization in the absence and presence of HSA-heme-Fe(III) allows us to obtain, in the absence of ibuprofen and both in the absence and presence of CO 2 , at 22.0°C, the values of pK a , k lim(top) and k lim(bottom) (67, 70 -72) according to Equation 4 ,
where k is k 0 or k on , and k lim(top) represents the top asymptotic value of k under conditions where pH Ͻ Ͻ pK a , and Equation 5,
where k is k 0 or k on , and k lim(top) and k lim(bottom) represent the asymptotic values of k under conditions where pH Ͻ Ͻ pK a or pH Ͼ Ͼ pK a , respectively. The value of the dissociation equilibrium constant for ibuprofen binding to HSA-heme-Fe(III) (L) was determined, at pH 7.2, from the dependence of k on i on the ibuprofen concentration (ranging between 5.0 ϫ 10 Ϫ5 and 1.0 ϫ 10 Ϫ2 M). The effect of ibuprofen concentration on k on i was analyzed according to Equation 6 (30, 51, 71) ,
where k on(top) i represents the asymptotic value of k on i under conditions where
Ϫ and NO 3 Ϫ analysis was carried out spectrophotometrically at 543 nm by using the Griess reagent and VCl3 to catalyze the conversion of NO 3 Ϫ to NO 2 Ϫ , as described previously (70, 75, 76) . Calibration curves were obtained by measuring 4 -8 standard sodium nitrite and sodium nitrate solutions in 1.0 ϫ 10 Ϫ1 M phosphate buffer, pH 7.2, and 22.0°C. The samples were prepared by mixing 500 l of a HSA-heme-Fe(III) solution (initial concentration, 1.0 ϫ 10 Ϫ4 M in 2.0 ϫ 10 Ϫ1 M phosphate buffer, pH 7.2) with 500 l of a peroxynitrite solution (initial concentration, 4.0 ϫ 10 Ϫ4 M in 1.0 ϫ 10 Ϫ2 M NaOH) while vortexing, at 22.0°C, in the absence and presence of CO 2 (1.2 ϫ 10 Ϫ3 M) and ibuprofen (2.5 ϫ 10 Ϫ3 M). The reaction mixture was analyzed within ϳ10 min. At least four separate experiments were carried out.
The reaction of peroxynitrite with free L-tyrosine was carried out at pH 7.2 and 22.0°C by adding 0.2 ml of an alkaline ( and CO 2 (final concentration, 1.2 ϫ 10 Ϫ3 M), as previously reported (67, 70) .
The amount of nitro-L-tyrosine was determined by HPLC, as reported previously (67, 70) . The chromatographic system consisted of a Waters 600 pump and a Waters autosampler 717 PLUS equipped with a spectrophotometric UV-visible dual wavelength system, Waters 2487 (Waters, Milford, MA). Nitro-L-tyrosine separation was performed at 24.0°C on the Grace Vydac 218TP54 Protein&Peptide C18 column (250 ϫ 4.6 mm) equipped with a Grace Vydac guard cartridge filled with the same packing material (Grace Vydac, Columbia, MD). The mobile phase was composed of solutions A (0.07% trifluoroacetic acid in H 2 O) and B (0.07% trifluoroacetic acid in acetonitrile). Both solutions were degassed by purging with helium. The injection volume was 20 l. Nitro-L-tyrosine was eluted (7.48 Ϯ 0.05 min after injection) by keeping the amount of solvent B constant (5%) in the first 2 min and then by using an increasing linear gradient of B from 5 to 10% between 2 and 10 min and from 10 to 80% between 10 and 15 min. Nitro-L-tyrosine was detected at 220, 280, 350, and 400 nm. Nitro-L-tyrosine was quantified by measuring a calibration curve of seven nitro-L-tyrosine standard solutions. The Millenium software (Waters) was used to pilot the HPLC instrument and to process the data (i.e. area integration, calculation, and plotting of chromatograms) throughout the method validation and sample analysis.
The value of the dissociation equilibrium constant for ibuprofen binding to HSA-heme-Fe(III) (L) was determined, at pH 7.2 and 22.0°C, from the dependence of the relative yield of nitro-L-tyrosine formed from the reaction of peroxynitrite with free L-tyrosine (Y) on the drug concentration ([ibuprofen] , ranging between 2.0 ϫ 10 Ϫ4 and 5.0 ϫ 10 Ϫ3 M). The effect of the ibuprofen concentration on Y was analyzed according to Equation 7 (30, 51, 71) ,
where R corresponds to Y in the absence of ibuprofen.
The value of the dissociation equilibrium constant for ibuprofen binding to HSA-heme-Fe(III) (L) was also obtained spectrophotometrically at 404 nm (by a Cary 50 Bio spectrophotometer; Varian Inc., Palo Alto, CA), using an optical cell with 1.0-cm path length, at 22.0°C. Small aliquots of the 1.2 ϫ 10 Ϫ2 M heme-Fe(III) and 1.0 ϫ 10 Ϫ3 M HSA solutions were diluted in the optical cell in 1.0 ϫ 10 Ϫ1 M phosphate buffer, 10% DMSO, pH 7.0, to a final HSA-heme-Fe(III) concentration of 1.0 ϫ 10 Ϫ5 M. Then small aliquots of the 1.0 ϫ 10 Ϫ3 M ibuprofen solution were added to the HSA-heme-Fe(III) solution, and the absorbance spectra were recorded after incubation for a few minutes after each addition. Ibuprofen binding to HSA-hemeFe(III) was analyzed by plotting the Soret band absorbance change (⌬A) as a function of the ibuprofen concentration. Data were analyzed according to Equation 8 (30, 51, 71) ,
where ⌬A max is the absorbance change at saturating ibuprofen concentration.
Kinetic and thermodynamic data were analyzed using the MatLab program (The Math Works Inc., Natick, MA). The results are given as mean values of at least four experiments Ϯ S.D.
RESULTS
HSA-Heme(III) Catalyzes Peroxynitrite Isomerization-
The kinetics of peroxynitrite isomerization, both in the absence and presence of HSA-heme-Fe(III), HSA-heme-Fe(III)-CN, HSA, and CO 2 , was recorded by a single-wavelength stopped-flow apparatus. Under all of the experimental conditions, a decrease of the absorbance at 302 nm was observed, as previously reported (67, 69, 70, (72) (73) (74) . The kinetics of peroxynitrite isomerization was fitted to a single-exponential decay for more than 97% of its course (supplemental Fig. S1 ). According to the literature (67, 70) , this indicates that no intermediate species (e.g. HSA-heme-Fe(III)-OONO; see Scheme 2) accumulate(s) in the course of peroxynitrite isomerization. In particular, the formation of the transient HSA-heme-Fe(III)-OONO species represents the rate-limiting step in catalysis, the conversion of the HSA-heme-Fe(III)-OONO complex to HSA-heme-Fe(III) and NO 3 Ϫ being faster by at least 1 order of magnitude. In the absence of CO 2 , the observed rate constant for HSAheme-Fe(III)-catalyzed isomerization of peroxynitrite (k obs ) increases linearly with the HSA-heme-Fe(III) concentration over the whole pH range explored ( Fig. 2A) . The analysis of data reported in Fig. 2A , according to Equation 2, allowed the determination of values of the first-order rate constant for peroxynitrite isomerization in the absence of HSA-heme-Fe(III) (k 0 ; corresponding to the y intercept of the linear plots) and of the second-order rate constant for peroxynitrite isomerization by HSA-heme-Fe(III) (k on ; corresponding to the slope of the linear plots). Values of k 0 for peroxynitrite isomerization in the absence of HSA-heme-Fe(III) ( Table 1 ) are in good agreement with those obtained in the presence of HSA-heme-Fe(III)-CN and HSA (Fig. 2B) and reported in the literature (67, 70, 72, 74) .
Because of the physiological relevance attributed to the reaction between CO 2 and peroxynitrite (79, 74, (77) (78) (79) , the effect of the physiological concentration of CO 2 on peroxynitrite isomerization by HSA-heme-Fe(III), HSA-heme-Fe(III)-CN, and HSA has been investigated. As shown in Fig. 2C , HSAheme-Fe(III) catalyzes the isomerization of peroxynitrite in a concentration-dependent linear fashion. The analysis of data reported in Fig. 2C , according to Equation 2, allowed the determination of values of the first-order rate constant for peroxynitrite isomerization in the absence of HSA-heme-Fe(III) (k 0 ; corresponding to the y intercept of the linear plots) and of the second-order rate constant for peroxynitrite isomerization by HSA-heme-Fe(III) (k on ; corresponding to the slope of the linear plots). In the presence of CO 2 , values of k 0 for peroxynitrite isomerization in the absence of HSAheme-Fe(III) ( (74, 79) . To confirm the catalytic effect of HSA-heme-Fe(III) on peroxynitrite isomerization, the dependence of k obs and k 0 on the peroxynitrite concentration was determined in the absence and presence of HSA-heme-Fe(III), HSA-heme-Fe(III)-CN, HSA, and CO 2 concentration, at pH 6.2 (data not shown), 7.2 ( Fig. 3) , and 8.1 (data not shown). Under all the experimental conditions, values of k obs and k 0 for peroxynitrite isomerization slightly decrease upon increasing peroxynitrite concentration. In contrast, the amplitude of the kinetics increases as a function of the peroxynitrite concentration (data not shown). The decrease of k obs and k 0 values upon increasing peroxynitrite concentration at fixed HSA-heme-Fe(III) concentration in the absence and presence of CO 2 (Fig. 3) is reminiscent of what has been reported for peroxynitrite isomerization by human HbFe(III) and horse heart Mb-Fe(III) (70) . This behavior has been proposed to reflect the occurrence of the peroxynitrite/peroxynitrous acid adduct at [peroxynitrite] Ͼ 5.0 ϫ 10 Ϫ5 M, around neutrality (70) . Accordingly, the decrease of k obs and k 0 values upon increasing the peroxynitrite concentration may reflect either the slow HSA-heme-Fe(III)-mediated decomposition of the peroxynitrite/peroxynitrous acid adduct or the slow dissociation of the peroxynitrite/peroxynitrous acid adduct preceding HSA-heme-Fe(III)-catalyzed peroxynitrite isomerization.
To highlight the role of the heme-Fe(III) atom to catalyze peroxynitrite isomerization, the effect of HSA-hemeFe(III)-CN and HSA concentration on the isomerization of peroxynitrite was investigated in the absence and presence of CO 2 . As shown in Fig. 2, B and D, HSA-heme-Fe(III)-CN and HSA do not affect the peroxynitrite isomerization kinetics. Therefore, the acceleration of the peroxynitrite isomerization rate by HSA-heme-Fe(III) could be due to the reaction of peroxynitrite with the heme-Fe(III) atom, as reported for human Hb-Fe(III) and horse heart Mb-Fe(III) (70) . The pH dependence of k 0 and k on for peroxynitrite isomerization, in the absence and presence of HSA-heme-Fe(III) and CO 2 , was examined to identify tentatively the species that preferentially react(s) with HSA-heme-Fe(III). Values of k 0 and k on shown in Fig. 4 were derived from data reported in Fig. 2 , A and C, and are listed in Table 1 . Values of k 0 for peroxynitrite isomerization in the absence of HSA-heme-Fe(III) and CO 2 decrease upon increasing pH from 6.2 to 8.1 (Fig. 4A ). In contrast, values of k 0 for peroxynitrite isomerization in the absence of HSA-heme-Fe(III) but in the presence of CO 2 increase upon raising the pH from 6.2 to 8.1 (Fig. 4B) . In the absence and presence of CO 2 , the pH dependence of k on values for HSAheme-Fe(III)-mediated isomerization of peroxynitrite (Fig. 4C) is closely similar to that of k 0 for peroxynitrite isomerization in the absence of HSA-heme-Fe(III) and CO 2 (Fig. 4A) . The analysis of data reported in Fig. 4 , according to Equations 4 and 5, allowed the estimation of pK a values for the pH dependence of k 0 and k on values for peroxynitrite isomerization in the absence and presence of HSA-heme-Fe(III) and CO 2 .
The pH dependence of k 0 for peroxynitrite isomerization in the absence of both HSA-heme-Fe(III) and CO 2 (pK a ϭ 6.8) (Fig. 4A) and of k on for peroxynitrite isomerization by HSAheme-Fe(III) in the absence and presence of CO 2 (pK a ϭ 6.9) (Fig. 4C) is similar. The pK a value (6.8) for the pH dependence of k 0 for peroxynitrite isomerization in the absence of both HSA-heme-Fe(III) and CO 2 here determined is in excellent agreement with pK a values reported in the literature (74) . In contrast, the pH dependence of k 0 for peroxynitrite isomerization in the absence of HSA-heme-Fe(III) but in the presence of CO 2 (pK a ϭ 7.6) (Fig. 4B) is different from that of k 0 for peroxynitrite isomerization in the absence of both HSA-hemeFe(III) and CO 2 (pK a ϭ 6.8) (Fig.  4A) and of k on for peroxynitrite isomerization by HSA-heme-Fe(III) in the absence and presence of CO 2 (pK a ϭ 6.9) (Fig. 4C) .
According to the literature (67, 70), the close similarity of the pH dependence of k 0 for peroxynitrite isomerization in the absence of both HSA-heme-Fe(III) and CO 2 (pK a ϭ 6.8) (Fig. 4A) and of k on for peroxynitrite isomerization by HSAheme-Fe(III) in the absence and presence of CO 2 (pK a ϭ 6.9) (Fig.  4C) suggests that in all cases, HOONO is the species that reacts preferentially with the heme-Fe(III) atom. Conversely, the different pK a value observed for peroxynitrite isomerization in the presence of CO 2 and in the absence of HSA-heme-Fe(III) (pK a ϭ 7.6) (Fig.  4B ) could indicate that the species undergoing the isomerization is a transient highly reactive intermediate(s) formed by the reaction of peroxynitrite with CO 2 . Since peroxynitrite has been reported to react with CO 2 , leading to the formation of an adduct whose composition is believed to be ONOOC(O)O Ϫ (named 1-carboxylato-2-nitrosodioxidane) (74, 79) , this might be the transient species that then converts to NO 3 Ϫ and CO 2 either directly or by transient formation of trioxocarbonate( ⅐ 1-) (CO 3 . ) and ⅐ NO 2 . On the other hand, the similar pK a values for peroxynitrite isomerization by HSA-heme-Fe(III), both in the absence and in the presence of CO 2 (pK a ϭ 6.9), indicates that peroxynitrite reacts with HSA-heme-Fe(III) as HOONO.
Ibuprofen Impairs HSA-Heme-Fe(III)-mediated Isomerization of Peroxynitrite-
In the absence and presence of CO 2 , ibuprofen impairs dose-dependently HSA-heme-Fe(III)-mediated isomerization of peroxynitrite (Fig. 5) . Mixing HSA-hemeFe(III) with peroxynitrite, in the presence of ibuprofen and in the absence and presence of CO 2 , brings about a decrease of the absorbance at 302 nm (supplemental Fig. S2, A and B) . Moreover, the kinetics of peroxynitrite isomerization by HSA-hemeFe(III), in the presence of ibuprofen and in the absence and presence of CO 2 , was fitted to a single-exponential decay for more than 97% of its course (supplemental Fig. S2, A and B) . These findings agree with the results concerning peroxynitrite isomerization in the absence of ibuprofen (see above and supplemental Fig. S1 ).
The observed rate constant for HSA-heme-Fe(III)-catalyzed isomerization of peroxynitrite (k obs i ) increases linearly with the HSA-heme-Fe(III) concentration over the whole ibuprofen concentration range explored, in the absence and presence of Table 1 ). The peroxynitrite concentration was 2. Table  2 ). The analysis of the dependence of k on i for HSA-heme(III)-catalyzed isomerization of peroxynitrite, according to Equation 4 , allowed the determination of the CO 2 -independent value of the dissociation equilibrium constant for ibuprofen binding to HSA-heme-Fe(III) (L ϭ 9.7 ϫ 10 Ϫ4 M).
Analysis of the Nitrogen-containing Products of Peroxynitrate
Isomerization-According to the literature (70, 80) , the spontaneous isomerization of peroxynitrite yielded 76 Ϯ 4% NO 3 Ϫ and 23 Ϯ 3% NO 2 Ϫ . In the presence of HSA-heme-Fe(III), the NO 3 Ϫ and NO 2 Ϫ yields increased (ϳ90%) and decreased (ϳ10%), respectively, as reported for peroxynitrite isomerization catalyzed by human Hb-Fe(III) and horse heart Mb-Fe(III) (70) . The same result has been observed in the presence of HSA-hemeFe(III) and/or CO 2 , according to the literature (70, 80) . Last, ibuprofen does not significantly affect the NO 3 Ϫ and NO 2 Ϫ yields (supplemental Table S1 ).
Ibuprofen Impairs HSA-Heme-Fe(III)-based Protection of Free L-Tyrosine against Peroxynitrite-mediated Nitration-To
investigate the protective role of HSA-heme-Fe(III) against peroxynitrite-mediated nitration, the relative yield of nitro-Ltyrosine formed by the reaction of peroxynitrite with free L-tyrosine in the presence of HSA-heme-Fe(III) was determined. For this purpose, 0.2 ml of a peroxynitrite solution were mixed with a free L-tyrosine solution, in the absence and presence of HSA-heme-Fe(III), HSA-heme-Fe(III)-CN, HSA, ibuprofen, and CO 2 , as previously reported (67, 70) . Note that CO 2 facilitates peroxynitrite-mediated nitration of L-tyrosine, redirecting peroxynitrite specificity (69, 74, 79) .
As shown in Fig. 6 , HSA-heme-Fe(III) protects dose-dependently free L-tyrosine against peroxynitrite-mediated nitration. In contrast, L-tyrosine nitration is not prevented by HSA-hemeFe(III)-CN and HSA, and the relative nitro-L-tyrosine yield corresponds to that observed in the absence of HSA derivatives. According to previous results (67, 70), HSA-heme-Fe(III) was slightly less efficient at preventing peroxynitrite-mediated nitration of free L-tyrosine in the presence than in the absence of CO 2 .
The ability of ibuprofen to impair allosterically HSA-hemeFe(III)-mediated peroxynitrite isomerization prompted us to investigate the role of this drug in modulating peroxynitritebased L-tyrosine nitration, in the absence and presence of CO 2 . The relative yield of nitro-L-tyrosine increased upon increasing the ibuprofen concentration, at fixed HSA-heme-Fe(III), peroxynitrite, L-tyrosine, and CO 2 concentration (Fig. 7) . The analysis of the data, according to Equation 7 , allowed the determination of values of the dissociation equilibrium constant L in the absence and presence of CO 2 (8.7 ϫ 10 Ϫ4 and 8.4 ϫ 10 Ϫ4 M, respectively).
Spectrophotometric Evidence for Ibuprofen Binding to HSA-Heme-Fe(III)-To further support ibuprofen binding to
HSA-heme-Fe(III), the value of the dissociation equilibrium constant for complex formation (L) has been determined spectrophotometrically (Fig. 8) . The analysis of the data, according to Equation 6 , allowed the determination of the dissociation equilibrium constant L (7.7 ϫ 10 Ϫ4 M). The value of L obtained spectrophotometrically (7.7 ϫ 10 Ϫ4 M) (Fig. 8) is in excellent (Fig. 5C ) and (ii) the relative nitro-L-tyrosine yield in the absence and presence of CO 2 (L ϭ 8.7 ϫ 10 Ϫ4 and 8.4 ϫ 10 Ϫ4 M, respectively) (Fig. 7) . Note that the heme-Fe(III)-ibuprofen complex, which could potentially interfere, only occurs at an ibuprofen concentration of Ն7.5 ϫ 10 Ϫ2 (38).
DISCUSSION
Ibuprofen, the prototype ligand of Sudlow's site II (1, 3, 26, 58) , modulates allosterically peroxynitrite isomerization by HSA-heme-Fe(III) and therefore the peroxynitrite-mediated nitration of free L-tyrosine, highlighting the role of heterotropic ligands on the HSA reactivity (11, 13, 52, 81) .
Peroxynitrite isomerization is facilitated by the HSAheme-Fe(III) species, whereas the HSA-heme-Fe(III)-CN derivative and the heme-free HSA are both non-reactive, clearly demonstrating that the efficiency of the isomerization process mirrors the heme-Fe(III) reactivity. As already reported for horse and sperm whale Mb and human Hb (67, 70) , peroxynitrous acid appears to be the species that preferentially reacts with HSA-heme-Fe(III). In addition, like horse heart Mb, sperm whale Mb, and human Hb (67, 70) , HSA-heme-Fe(III) protects free L-tyrosine from peroxynitrite-mediated nitration.
Allosteric inhibition of the HSA-heme-Fe(III)-mediated peroxynitrite isomerization by ibuprofen is related to drugdependent structural changes occurring at the FA1 site (i.e. at the heme binding pocket). Indeed, UV-visible, resonance Raman, and electron paramagnetic resonance spectroscopies evidenced that the pentacoordinated heme-Fe(III) atom of HSA-heme-Fe(III), observed in the absence of ibuprofen, becomes hexacoordinated low spin upon ibuprofen binding (38) . On the basis of the crystal structure of HSA-hemeFe(III) (21), the His 146 residue was suggested as the putative ligand able to coordinate to the heme-Fe(III) atom in the sixth position upon ibuprofen binding (38) . In contrast, in both ibuprofen-free pentacoordinated and ibuprofen-bound hexacoordinated HSA-heme-Fe(III), the Tyr 161 residue coordinates to the heme-Fe(III) atom in the fifth position (38) . Therefore, the presence of a strong ligand (either the His 146 residue or the exogenous cyanide ligand) at the sixth coordination position of the heme-Fe(III) atom inhibits peroxynitrite isomerization, thus rendering HSA-heme-Fe(III) non-reactive.
The identity of the ibuprofen binding pocket(s) (among the three possible ones, namely FA2, FA6, and Sudlow's site II) responsible for this allosteric effect is still unclear.
Structural and solution studies of ibuprofen binding to HSA have shown that the ibuprofen primary binding site (i.e. Sudlow's site II formed by FA3 and FA4 clefts) does not appear to be allosterically linked to the heme binding site (i.e. FA1) (30, 37, 38, 55) , ruling out the possibility that Sudlow's site II is responsible for the effect of ibuprofen on peroxynitrite isomerization by HSA-heme-Fe(III).
An additional candidate might be the ibuprofen secondary site FA6, which modulates negatively heme-Fe(III) binding to FA1 (12, 37) and the affinity of the secondary drug binding cleft FA2 (34, 37, 38, 81) . The FA6 site (located within domain II at the interface between subdomains IIA and IIB) is in close structural and functional contact with Sudlow's site I (i.e. the warfarin binding site), which is allosterically linked to the heme binding cleft (i.e. FA1) (12, 37) . However, since the dissociation equilibrium constant for ibuprofen binding to the FA6 site has been reported to fall in the 4.0 ϫ 10 Ϫ7 to 1.3 ϫ 10 Ϫ5 M range (depending on the absence and presence of allosteric effector(s)) (55), we can also rule out that the effect of ibuprofen on peroxynitrite isomerization is related to drug binding to the FA6 site. Indeed, the average value of the dissociation equilibrium constant for ibuprofen binding to HSA-heme-Fe(III) here determined (L) from the dependence of either k on or the relative yield of nitro-L-tyrosine or spectrophotometric changes in the Soret band on the ibuprofen concentration is at least 50-fold higher (8.8 ϫ 10 Ϫ4 M) (Figs. 6 -8) .
As a whole, FA2, the only ligand binding site that provides contacts with different HSA subdomains (being located at the interface between subdomains IIA and IIB), could represent the ibuprofen secondary cleft functionally linked to the heme-Fe(III) atom reactivity (37) . Thus, the average value of L (8.8 ϫ 10 Ϫ4 M) here determined (Figs. 6 -8) could reflect ibuprofen binding to the FA2 site of HSA-heme-Fe(III). Noticeably, this L value is grossly similar to that obtained from the ibuprofen-dependent resonance Raman spectroscopic changes of HSA-heme-Fe(III), reflecting hexacoordination of the heme-Fe(III) atom (L ϭ 4.0 ϫ 10 Ϫ4 M) (38) . Peroxynitrite isomerization by heme-Fe(III) proteins (e.g. HSA-heme-Fe(III)) could represent a physiological detoxification mechanism, protecting cells from reactive nitrogen and oxygen species (78) . Note that values of k on for peroxynitrite isomerization by HSA-heme-Fe(III) are higher by about 1 order of magnitude than those reported for ferric horse heart Mb, sperm whale Mb, human Hb, and heme-model compounds (67, 70, 82, 83) (supplemental Table S2 ). Moreover, peroxynitrite isomerization by HSA-heme-Fe(III) (supplemental Table S2 ) is faster than peroxynitrite scavenging by ferrous nitrosylated heme proteins, which appears to be strongly limited by (i) the dissociation of the transient hemeFe(III)-NO and (ii) the reduction of the final heme-Fe(III) species to the heme-Fe(II) derivative (50) . Remarkably, peroxynitrite isomerization by heme-Fe(III) proteins (e.g. HSAheme-Fe(III)) does not require any redox cycle.
Due to the relevant physiological role of HSA in human plasma, several in vivo implications can be argued from the present results. Indeed, peroxynitrite isomerization by HSAheme-Fe(III) could occur only in patients affected with a variety of severe hematologic diseases characterized by excessive intravascular hemolysis. Under these pathological conditions, the HSA-heme-Fe(III) plasmatic level increases from the physiological concentration (ϳ1 ϫ 10 Ϫ6 M) to ϳ4 ϫ 10 Ϫ5 M (59, 84), HSA acting as the main heme-Fe(III) plasma depot (84, 85) . To mimic as much as possible this condition, the HSA-hemeFe(III) concentration here used ranged from 5.0 ϫ 10 Ϫ6 to 5.0 ϫ 10 Ϫ5 M. The high heme plasma concentration is invariably associated with a reduction of hemopexin in patients affected by excessive intravascular hemolysis (59) . Note that upon increasing heme plasma level, hemopexin, whose plasma concentration (ϳ1.5 ϫ 10 Ϫ5 M) (84, 85) is about 2 orders of magnitude lower than that of HSA (7.5 ϫ 10 Ϫ4 M) (3), undergoes heme saturation, highlighting the role of HSA as a heme scavenger (84, 85) .
Although the in vivo concentration of peroxynitrite is openly debated, the level of peroxynitrite in the reperfused ischemic heart has been reported to be much higher than micromolar concentration, at least over brief period of time (86, 87) , overlapping with the lowest peroxynitrite concentration here used (2.5 ϫ 10 Ϫ5 M). Finally, considering the plasma level of ibuprofen (ϳ10 Ϫ4 to 10 Ϫ3 M) (88 -90) , the drug concentration here used ranged between 5.0 ϫ 10 Ϫ5 M and 1.0 ϫ 10 Ϫ2 M. Accounting for the average L value (ϳ8.8 ϫ 10 Ϫ4 M) here determined and the plasma level of ibuprofen, the molar fraction of the drugbound HSA-heme-Fe(III) could range between 10 and 50%.
CONCLUSIONS
Data here reported highlight the role of drugs in modulating HSA functions. This is relevant for the potential role played by HSA-heme in the detoxification process, also taking into account that the HSA-heme-Fe(III) plasmatic concentration increases significantly under pathological conditions (11, 13, 52, 59, 84) . Therefore, the higher HSA-heme concentration and the higher efficiency of peroxynitrite isomerization altogether contribute to identify HSA-heme as a major detoxification element in the bloodstream. This aspect acquires an even higher value in consideration of the protective role, played by the peroxynitrite isomerization, on the nitration of aromatic residues (such as tyrosine), which represent a relevant post-translational protein modification process (91) . Last, HSA, not only acting as a heme carrier but also displaying transient heme-based properties, represents a case for "chronosteric effects" (52) , which opens the scenario toward the possibility of a time-and metabolite-dependent multiplicity of roles for HSA. During the continuation of our work on hsc70 trafficking, we have noticed that there was an error during the preparation of midiprep plasmid DNA for two constructs that were described in this work. The error reported by us does not alter the validity of the raw data. The following two constructs were affected by the error: GFP-hsc70(225-262) and GFP-hsc70(245-287). These two plasmid DNAs have been inverted in our article. Following the detection of the error, we have verified the correctness of all other constructs encoding wild-type or mutant fragments of domain IIB of hsc70. This error affects the presentation of results shown in Figs. 2B and 3 (A and C) and the interpretation depicted in Fig. 6A . Thus, the correct interpretation of our data is that segment 245-287 locates constitutively in the nucleolus under nonstress and stress conditions. Fragment 225-262 displays weak stressinduced nucleolar accumulation. This makes residues 225-244 the negative regulator of hsc70 nucleolar accumulation. The experiments reported were carried out at 390 mM methyl-␤-cyclodextrin (M␤CD; 825 mg ϩ 1 ml of water, which gives a volume of ϳ1.6 ml), not as reported at 625 mM M␤CD (825 mg/ml of solution). We (MiJin Son and E. L.) have investigated asymmetric vesicle preparation at the higher M␤CD concentration and found that 625 mM M␤CD could be used to produce asymmetric small unilamellar vesicles. However, the results were not as reproducible as with the lower M␤CD concentration. We recommend the use of 390 mM M␤CD to prepare asymmetric small unilamellar vesicles. The first sentence in the Abstract should read as follows: The cyclic dinucleotide c-di-AMP synthesized by the diadenylate cyclase domain was discovered recently as a messenger molecule for signaling DNA breaks in Bacillus subtilis.
In the Introduction, line 21 in the right-hand column should read as follows: This group of proteins (COG3887), as represented by the B. subtilis protein YybT, contains two N-terminal transmembrane helices, a region that shares minimum sequence homology with some PerArnt-Sim (PAS) domains, a highly modified GGDEF domain, and a DHH/DHHA1 domain (see Fig. 1 ). 
